Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer

Oncology

Volumn 79, Issue 1-2, 2010, Pages 118-128

  Heinemann, Volker ^a   Hoff, Paulo M ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Bevacizumab; Chemotherapy; Efficacy; Irinotecan; Metastatic colorectal cancer; Safety

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HYPERTENSION; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG APPROVAL; EUROPE; FLUOROURACIL; HUMANS; LEUCOVORIN; MUTATION; ORGANOPLATINUM COMPOUNDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78349232458     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314993     Document Type: Review

References (53)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P, on behalf of the European Colorectal Metastases Treatment Group: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221.
3. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
4. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
7. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, on behalf of the Xeloda Colorectal Cancer Study Group: Oral capecita bine compared with intravenous fluoro uracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
8. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL, on behalf of the Capecitabine Colorectal Cancer Study Group: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
9. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K, on behalf of the Xeloda Colorectal Cancer Study Group: Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
10. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
11. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJL, van Bochove A, Sinnige HAM, Creemers GJM, Tesselaar MET, Slee PHTJ, Werter MJBP, Mol L, Dalesio O, Punt CJA: Sequential versus com bination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
12. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch- Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) (abstract 4030). J Clin Oncol 2008; 26(suppl):185s.
13. Ducreux M, Adenis A, Mendiboure J, François E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T: Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) (abstract 4086). J Clin Oncol 2009; 27(suppl):189s.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
15. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
16. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z: A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009; 24: 677-685.
17. Kopetz S, Glover Y, Eng C, Wolff RA, Chang DZ, Adinin RB, Morris J, Abbruzzese JL, Hoff PM: Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (abstract 4089). J Clin Oncol 2007; 25(suppl): 185s.
18. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690.
19. Falcone A, Masi G, Loupakis F, Vasile E, Ciarlo A, Cavaciocchi D, Amoroso D, Puglisi M, Fea E, Brunettiet I: FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group (abstract 4031). J Clin Oncol 2008; 26(suppl):185s.
20. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680.
21. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), irinotecan (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer (B-IFL) (abstract 489). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http://www.asco.org. Accessed February 10, 2009.
22. Vieitez J, Fonseca P, Crespo G, Berros J, Fernández de Sanmamed M, Muriel C, Izquierdo M, Pardo P, Esteban E, Lacave A: Results of a phase II study of capecitabine, CPT-11 (CAPIRI) and bevacizumab in chemotherapy- naïve stage IV colorectal cancer patients (abstract 404). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http://www.asco.org. Accessed February 10, 2009.
23. Welch S, Krzyzanowska M, Moore MJ, Mackay H, Knox JJ, Feld R, Petronis J, Blattler C, Wang L, Chen E: Phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) (abstract 475). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http://www.asco.org. Accessed February 11, 2009.
24. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, on behalf of AVIRI Trial Investigators: Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77: 113-119.
25. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
26. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, for the investigators of the BRiTE study: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
27. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 262: 5326-5334.
28. Moehler M, Sprinzl MF, Abdelfatah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S: Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15: 449-456.
29. Comella P, Massidda B, Natale D, Filippelli G, Farris A, Condemi G, Palmeri S, Tafuto S, Vessia G, Barberis G: Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the SICOG experience (abstract e15067). J Clin Oncol 2009. Available at: http://www.asco.org. Accessed June 28, 2010.
30. Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R: Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol 2009, E-pub ahead of print.
31. Garcia Alfonso P, Muñoz Martín A, Gonzalez del Val R, Parkam Khosravi S, Izarzugaza Perón Y, Arranz Cozar J, Cabezón Gutierrez L, Márquez-Rodas I, Soria Lobelle A, Pérez Manga G: Efficacy and safety of the first-line treatment with a combination of bevacizumab and biweekly XELIRI in metastatic colorectal cancer without previous treatment (abstract 431). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http://www.asco.org. Accessed February 10, 2009.
32. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ: Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26: 183-189
33. Seifert P, Baker LH, Reed ML, Vaitkevicius VK: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-128.
34. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/ leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
35. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd: A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006; 17: 1399-1403.
36. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
37. Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J: Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional or capecitabine with camptostar-celecoxib study. Cancer 2009; 115: 2617-2629.
38. Metges J, Grudé F, Faroux R, Achour N, Douillard J, Klein V, Ramée J, Etienne P, Ganem G, Riche C, Gamelin E: FOLFIRI bevacizumab in unresectable metastatic colorectal cancer (UMCC) in true life, feasibile in elderly patients (EP): results of the cohort from OMIT Bretagne-Pays de Loire (abstract 398). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http://www.asco.org. Accessed February 11, 2009.
39. Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W: Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups (abstract 3617). J Clin Oncol 2004; 22(suppl):274s.
40. Kozloff M, Sugrue MM, Berlin J, Flynn RJ, Kabbinavar F, Sargent D, Purdie DM, Dong W, Grothey A: Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with mCRC: results from the BRiTE observational cohort study (abstract 454). 2008 Gastrointestinal Cancers Symp, Orlando, January 2008. Available at: http://www. asco.org. Accessed June 29, 2010.
41. Santomaggio A, Ricevuto E, Cannita K, Bruera G, Tudini M, Lanfiuti Baldi P, Mancini M, Porzio G, Marchetti P, Ficorella C: 'Poker' schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: a phase II study (abstract 4125). J Clin Oncol 2009; 27(suppl):199s.
42. Falcone A: Combination chemotherapy and bevacizumab as first-line therapy in treating patients with metastatic colorectal cancer. Available at: http://www.clinicaltrials.gov. Accessed October 23, 2008.
43. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ: Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007; 13: 6231-6235.
44. Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with meta static colorectal cancer: a retrospective study. BMC Cancer 2009; 9: 347.
45. Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G: Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen. Anticancer Res 2008; 28: 3087-3092.
46. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of K-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989.
47. Hurwitz H, Yi J, Ince W, Novotny WF, Rosen O: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of k-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-28.
48. F. Hoffmann-La Roche Ltd.: Avastin (bevacizumab) Summary of Product Characteristics 2010. Available at: http://www.emea. europa.eu/humandocs/Humans/ EPAR/ avastin/avastin.htm 2008. Accessed June 29, 2010.
49. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E: Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16: 2745-2751.
50. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25: 4557-4561.
51. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
52. Skougaard K, Nielsen D, Pfeiffer P, Joergensen T, Bjerregaard JK, Jensen BV: Bevacizumab in combination with cetuximab and irinotecan (BCI) after failure of cetuximab and irinotecan (CI) in patients with metastatic colorectal cancer (mCRC) (abstract 482). 2009 Gastrointestinal Cancers Symp, San Francisco, January 2009. Available at: http:// www.asco.org. Accessed February 11, 2009.
53. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, Schrama JG, Erdkamp FL, Vos A, Mol L, Antonin NF: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) (abstract LBA4011). J Clin Oncol 2008; 26(suppl):1008s.